最新发布
2026年山东“十百千万”农机推广大行动暨诸城玉米适期晚收与机械化烘干技术推介活动举办
10月20日，2026年山东省“十百千万”农机推广大行动暨诸城市玉米适期晚收与机械化烘干技术推介活动举办。潍坊市农业农村局四级调研员王元志、潍坊市农业技术推广中心农机推广科科长李建友、潍坊市农业技术推广中心农机推…
In Conversation with Alex Hinson, President and CEO of RMS
By Autumn Demberger, AgInvesting Media Resource Management Services (RMS) is one of the largest providers of timberland …
New Study Maps Global Economic Potential of Smart Farming Innovations and Future Growth
By Editor, AgInvesting Media The intersection of technology and agriculture has increasingly become a focal point for re…
AgriFood Signals: Danone turns yogurt into renewable energy, Bison Ventures lands $160m, biochar projects
AgFunderNews rounds up the most important fundings, mergers, acquisitions, closures, and industry buzz in agtech and foo…
Ground Up Investing Reaches $6 Million First Close on Second Fund to Support Farmers Across Africa and Latin America
By Editor, AgInvesting Media Ground Up Investing (GUI), the impact investing arm of Washington, D.C.-based non-governmen…
Why Infrastructure-Focused Agritech Outperforms Consumer Apps
7 African agriculture has witnessed a wave of innovation over the past two decades, thanks to agritech solutions. With t…
China’s beauty paradox: Exports catch up to K-beauty despite domestic slowdown
China’s domestic online beauty sales are falling as C-beauty companies are ramping up export efforts and moving into international retail channels. The gap suggests a deliberate pivot from C-beauty toward overseas growth, targeting the categories and regions that K-beauty has spent the past decade winning over.
Dove and Clean Cult diversify with first-time fragrance and body care launches
Dove has entered fine fragrance, and the home cleaning brand Clean Cult has expanded into personal care. The moves demonstrate how brands are expanding into beauty categories new to them, catering to growth and specific demands across segments.
Beauty leads P&G Q1 FY2027 growth, driven by skin and hair care
Procter & Gamble (P&G) has reported net sales of US$23.3 billion for the first quarter of its fiscal year 2027 (July to September 2026), up 4% year-on-year. Organic sales, which exclude foreign exchange and acquisitions and divestitures, also grew 4%.
Roche bets up to $813M on Zymeworks lung cancer candidate
Why it matters: Roche is returning to a clinically validated cancer target with an unproven design. Amgen’s DLL3-targeted tarlatamab extended median survival to 13.6 months versus 8.3 months with chemotherapy in previously treated small-cell lung cancer patients. Roche discontinued its own DLL3-targeted trispecific after Phase 1, but is now betting that ZW209’s different approach to stimulating T cells could deliver better results, despite the absence of human efficacy data.